New cancer drug FID-022 enters first human trial
Disease control
Recruiting now
This early-phase trial tests a new drug called FID-022 in 24 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to find a safe dose and check for side effects. The drug contains two active components, including irinotecan, which is …
Phase: PHASE1 • Sponsor: Fulgent Pharma LLC. • Aim: Disease control
Last updated Jun 26, 2026 13:01 UTC